Literature DB >> 16985828

Early hormonal therapy for prostate cancer: the good, the bad, and the ugly.

Stephen J Freedland, Alan W Partin.   

Abstract

Entities:  

Year:  2005        PMID： 16985828      PMCID： PMC1477575     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  7 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

3.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

Review 4.  The physical burden of prostate cancer.

Authors:  David F Penson; Mark S Litwin
Journal:  Urol Clin North Am       Date:  2003-05       Impact factor: 2.241

5.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Authors:  Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Timothy Donahue; Leo Kusuda; Wade Sexton; Keith O'Reilly; Javier Hernandez; Andrew Chung; Douglas Soderdahl
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

6.  Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Authors:  Peter Iversen; Jan-Erik Johansson; Pär Lodding; Olavi Lukkarinen; Per Lundmo; Peter Klarskov; Teuvo L J Tammela; Ilker Tasdemir; Tom Morris; Kevin Carroll
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

7.  Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.

Authors:  Manfred P Wirth; William A See; David G McLeod; Peter Iversen; Tom Morris; Kevin Carroll
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450
  7 in total
  1 in total

1.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.